What is Xenon Pharmaceuticals Inc.'s Shariah compliance score?

Xenon Pharmaceuticals Inc.'s (XENE) compliance score is being calculated. Check HalalScreener.app for the latest AAOIFI screening results.

Does Xenon Pharmaceuticals Inc. pass AAOIFI screening?

Xenon Pharmaceuticals Inc. (XENE) does not pass AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (XENE: 0.2%), (3) interest-bearing deposits below 30% (XENE: 13.1%), and (4) prohibited income below 5% (XENE: 107.8%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for Xenon Pharmaceuticals Inc. stock?

Xenon Pharmaceuticals Inc. (XENE) has a non-permissible income ratio of 107.77%. Muslim investors should purify this percentage of any dividends received and capital gains realized from XENE shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen Xenon Pharmaceuticals Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Xenon Pharmaceuticals Inc. (XENE) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about XENE's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

Is Xenon Pharmaceuticals Inc. (XENE) halal? Not Halal. Based on AAOIFI screening, Xenon Pharmaceuticals Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

XENE: Is Xenon Pharmaceuticals Inc. Halal?

Not Halal

Xenon Pharmaceuticals Inc.

NASDAQHealthcareCA

$52.30

-2.08%

AvoidBorderlineClean

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Jun 17, 2026

Non-Compliant

Fails Shariah screening

0Score

Business Activity Screen

Passed

Checks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)

Financial Ratio Screen

Failed

Financial ratios must be below AAOIFI thresholds

Debt / Market Cap0.2% / 30.0%

Compliance History

Not Halal, unchanged since May 2026.

No status changes recorded since we began tracking.

Tracked since May 2026. Updates automatically on each re-screen.

Screened: Jun 17, 2026Fiscal: Q1 2026Source: EDGAR

Financial Overview

Market Cap

4.1B

Price

$52.30

Sector

Healthcare

Industry

Biotechnology

Halal Alternatives in Healthcare

This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:

0001.KLA+

Supercomnet Technologies Bhd

$0.54

+0.00%

0002.KLA+

Kotra Industries Bhd

$3.75

+0.00%

0075.KLA+

LYC Healthcare Bhd

$0.02

+0.00%

0101.KLA+

TMC Life Sciences Bhd

$0.45

+0.00%

0155.KLA+

Malaysian Genomics Resource Centre Bhd

$0.27

+0.00%

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track XENE and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Xenon Pharmaceuticals Inc. (XENE) halal to invest in?

Xenon Pharmaceuticals Inc. (XENE) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.

Why did Xenon Pharmaceuticals Inc. get a F compliance rating?

Xenon Pharmaceuticals Inc. (XENE) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 0.2% (limit 30%); interest-bearing deposits of 13.1% (limit 30%); prohibited income of 107.77% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Xenon Pharmaceuticals Inc.'s Shariah verdict?

Xenon Pharmaceuticals Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Xenon Pharmaceuticals Inc. re-screened for Shariah compliance?

Xenon Pharmaceuticals Inc. (XENE) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jun 17, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.